Zoetis Inc. (ZTS)

Symbol Overview

ZTShttp://www.nasdaq.com/symbol/ztsHealth Care2013Major Pharmaceuticals

Latest Zoetis Inc. (ZTS) company news

CTLT vs. ZTS: Which Stock Should Value Investors Buy Now?

Escalating U.S.-China trade-war tensions and heightening political uncertainties pull U.S. bank stocks down.

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalent (CTLT) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.

Right now, Catalent is sporting a Zacks Rank of #2 (Buy), while Zoetis has a Zacks Rank of #3 (Hold). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that CTLT has an improving earnings outlook. But this is just one factor that value investors are interested in.

Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.

Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.

CTLT currently has a forward P/E ratio of 24.93, while ZTS has a forward P/E of 28.55. We also note that CTLT has a PEG ratio of 1.88. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ZTS currently has a PEG ratio of 1.93.

Another notable valuation metric for CTLT is its P/B ratio of 5.22. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, ZTS has a P/B of 21.38.

These are just a few of the metrics contributing to CTLT's Value grade of B and ZTS's Value grade of C.

CTLT is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that CTLT is likely the superior value option right now.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Catalent, Inc. (CTLT) : Free Stock Analysis Report
 
Zoetis Inc. (ZTS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.

Free Stock Performance Review on Zoetis and Three Additional Generic Drugs Stocks

Stock Research Monitor: FLXN, MNTA, and PETQ

LONDON, UK / ACCESSWIRE / June 19, 2018/ If you want a free Stock Review on ZTS sign up now at www.wallstequities.com/registration. WallStEquities.com shifts focus on the Generic Drugs industry, which is not only armed to survive battles over patents, but also to adopt licensing and partnering strategies to launch new products successfully and ensure that their market thrives. Under evaluation this morning are these four stocks: Flexion Therapeutics Inc. (NASDAQ: FLXN), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), PetIQ Inc. (NASDAQ: PETQ), and Zoetis Inc. (NYSE: ZTS). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Flexion Therapeutics

Burlington, Massachusetts headquartered Flexion Therapeutics Inc.'s stock finished Monday's session 1.02% higher at $26.76 with a total trading volume of 210,892 shares. Over the last month and the previous three months, the Company's shares have advanced 0.45% and 14.07%, respectively. Additionally, the stock has gained 55.58% over the past year. The stock is trading above their 50-day and 200-day moving averages by 2.95% and 7.82%, respectively. Moreover, shares of Flexion Therapeutics, which focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, have a Relative Strength Index (RSI) of 52.24.

On June 01st, 2018, Flexion Therapeutics announced a grant of inducement stock options to eight new employees for an aggregate of 50,000 shares of common stock. The Compensation Committee of the Board of Directors approved the grants, with an effective date of June 01st, 2018. The stock options have an exercise price of $27.01 per share and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Get the full research report on FLXN for free by clicking below at:

www.wallstequities.com/registration/?symbol=FLXN


Momenta Pharmaceuticals

Shares in Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc. rose 2.74%, ending yesterday's session at $22.50 with a total trading volume of 487,194 shares. The stock has gained 23.29% in the previous three months and 35.14% over the past year. The Company's shares are trading 3.45% above their 50-day moving average and 31.99% above their 200-day moving average. Moreover, share of Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the US, have an RSI of 45.94. Find your free research report on MNTA at:


www.wallstequities.com/registration/?symbol=MNTA


PetIQ

On Monday, Eagle, Idaho headquartered PetIQ Inc.'s stock declined slightly by 0.70%, to close the day at $22.66. A total volume of 513,504 shares was traded, which was above their three months average volume of 421,410 shares. The Company's shares have advanced 24.16% in the last month. The stock is trading 8.76% above its 50-day moving average. Additionally, shares of PetIQ, which develops, manufactures, and distributes pet medications, and health and wellness products for dogs and cats in the US, Canada, and Europe, have an RSI of 65.35.

On June 06th, 2018, PetIQ announced that management will participate in the Jefferies 2018 Consumer Conference in Nantucket, Massachusetts. The presentation will be on June 20th, 2018, at 10:00 a.m. ET. It can be accessed live under the "Investors" section of the Company's website. Sign up today for the free research report on PETQ at:

www.wallstequities.com/registration/?symbol=PETQ

Zoetis

Shares in Parsippany, New Jersey headquartered Zoetis Inc. ended the day 0.30% lower at $88.93. A total volume of 3.52 million shares was traded, which was above their three months average volume of 2.44 million shares. The stock has gained 7.21% in the last month, 6.95% in the previous three months, and 42.17% over the past year. The Company's shares are trading above their 50-day and 200-day moving averages by 5.51% and 17.89%, respectively. Furthermore, shares of Zoetis, which discovers, develops, manufactures, and markets veterinary vaccines and medicines in the US and internationally, have an RSI of 67.68. Wall St. Equities' research coverage also includes the downloadable free report on ZTS at:

www.wallstequities.com/registration/?symbol=ZTS

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

Does Zoetis Inc’s (NYSE:ZTS) Past Performance Indicate A Stronger Future?

View photos

After looking at Zoetis Inc’s (NYSE:ZTS) latest earnings announcement (31 March 2018), I found it useful to revisit the company’s performance in the past couple of years and assess this against the most recent figures. As a long term investor, I pay close attention to earnings trend, rather than the figures published at one point in time. I also compare against an industry benchmark to check whether Zoetis’s performance has been impacted by industry movements. In this article I briefly touch on my key findings. See our latest analysis for Zoetis

How Did ZTS’s Recent Performance Stack Up Against Its Past?

I prefer to use the ‘latest twelve-month’ data, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. This technique allows me to examine many different companies on a similar basis, using new information. For Zoetis, its most recent earnings (trailing twelve month) is US$978.00M, which, relative to last year’s figure, has increased by 14.49%. Since these values are somewhat short-term thinking, I have calculated an annualized five-year figure for ZTS’s net income, which stands at US$561.77M This suggests that, on average, Zoetis has been able to consistently improve its bottom line over the past few years as well.

NYSE:ZTS Income Statement Jun 15th 18

What’s enabled this growth? Let’s take a look at whether it is solely a result of an industry uplift, or if Zoetis has experienced some company-specific growth. In the last few years, Zoetis increased its bottom line faster than revenue by efficiently controlling its costs. This resulted in a margin expansion and profitability over time. Eyeballing growth from a sector-level, the US pharmaceuticals industry has been growing its average earnings by double-digit 11.56% over the prior twelve months, and a less exciting 9.52% over the previous five years. This means that any uplift the industry is gaining from, Zoetis is able to leverage this to its advantage.

What does this mean?

While past data is useful, it doesn’t tell the whole story. Companies that have performed well in the past, such as Zoetis gives investors conviction. However, the next step would be to assess whether the future looks as optimistic. You should continue to research Zoetis to get a better picture of the stock by looking at:

  1. Future Outlook: What are well-informed industry analysts predicting for ZTS’s future growth? Take a look at our free research report of analyst consensus for ZTS’s outlook.
  2. Financial Health: Is ZTS’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

NB: Figures in this article are calculated using data from the trailing twelve months from 31 March 2018. This may not be consistent with full year annual report figures.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.

Blog Exposure - Regeneron Inks Five-Year Collaboration Deal with Zoetis to Discover Antibody Therapies in Animal Health

LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Regeneron Pharma, Inc. (NASDAQ: REGN) ("Regeneron"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=REGN as the Company's latest news hit the wire. On June 06, 2018, the Company announced that it has inked a five-year collaboration deal with Zoetis Inc. (NYSE: ZTS), which is a global animal health Company. The deal is aimed at researching the use of Regeneron's monoclonal antibody therapeutics in animals, and discover new veterinary treatments. The financial details of the deal remained undisclosed. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Regeneron Pharma and Zoetis most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=REGN

www.active-investors.com/registration-sg/?symbol=ZTS

Terms of the Collaboration Deal

  • Regeneron has granted Zoetis a license for its VelocImmune® antibody technology, which the latter will use to develop monoclonal antibodies modified for species-specific use in companion and livestock animals. The focused areas will be allergic and immune-related conditions, pain, inflammatory diseases, and cancer.
  • Regeneron will receive a license fee, approval and sales milestone payments, and royalties on any potential veterinary treatments.
  • Regeneron will also select antibodies from its pipeline for Zoetis to evaluate in dogs and cats that have certain naturally-occurring diseases, such as osteoarthritis. The data generated using this approach can help provide valuable information for potential new veterinary therapeutics.

VelocImmune® is Regeneron's proprietary technology in which the immune system of mice is genetically humanized, enabling the creation of fully-human and optimized antibody drug candidates.

Collaboration Extends Valuable Tools to Development of Monoclonal Antibodies Modified for Species-Specific Use in Animals

Drew Murphy, Ph.D., Senior Vice President of Research at Regeneron, stated that the Company's VelociSuite® drug discovery and development platforms have produced many important new medicines for people with serious medical conditions. Murphy added that this collaboration extends these valuable tools to the development of monoclonal antibodies modified for species-specific use in animals, an area Regeneron would not be exploring otherwise, and provides it with more information to develop safe and efficacious medicines for humans.

Deal will Enhance Zoetis' Internally-Developed Pipeline of Novel Monoclonal Antibodies

Commenting on the collaboration, Dr. Catherine Knupp, Executive Vice President and President, Research and Development at Zoetis, mentioned that the Company sees significant advantages from Zoetis and Regeneron scientists sharing knowledge and know-how across animal and human health. Knupp added that this collaboration will enhance Zoetis' internally-developed pipeline of novel monoclonal antibodies and hasten the development of therapeutics that could transform the way veterinarians treat a range of diseases in animals.

About Regeneron Pharmaceuticals, Inc.

Founded in 1988 and based in Tarrytown, New York, Regeneron is a leading biotechnology organization that invents life-transforming medicines for people with serious diseases. Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies to yield optimized fully-human antibodies, and ambitious initiatives.

About Zoetis Inc.

Headquartered in Parsippany, New Jersey, Zoetis is a global animal health Company dedicated to supporting customers and their businesses in ever better ways. Building on 60 years of experience, it delivers quality medicines and vaccines, complemented by diagnostic products, genetic tests, bio-devices, and a range of services.

Stock Performance Snapshot

June 07, 2018 - At Thursday's closing bell, Regeneron Pharma's stock declined 2.03%, ending the trading session at $308.72.

Volume traded for the day: 826.29 thousand shares.

Stock performance in the last month – up 8.00%

After yesterday's close, Regeneron Pharma's market cap was at $32.01 billion.

Price to Earnings (P/E) ratio was at 20.40.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: 73 29 92 6381

SOURCE:
Active-Investors

The Bull Case for Regeneron Pharmaceuticals Inc Couldn’t Be More Clear

After falling from $393 per share early this year to a recent low of $284 per share, analysts have begun pounding the table again for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN).

Regeneron is a biotech company known for drugs like Zaltrap, a cancer drug. The drugs and numbers have never interested me as much as its tools, like the Velocisuite, which gives researchers fast manipulation of mouse DNA, and TRAP — a general approach for developing enzyme blockers.

Regeneron has grown from sales of $2.1 billion in 2013 to $5.87 billion in 2017. Profitability is even better, with $1.2 billion hitting the net income line last year, and $478 million out of $1.5 billion in revenue making it to net income in the March quarter.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Fashion Over Results

With such steady profitable growth, you would expect a stock chart that goes straight up. Nope. Regeneron has traded as high as $577 per share in early 2015, when drugs were in fashion, and as low as $300 per share in May, when they were not.

Today, pharmaceuticals appear to be back in fashion. Suddenly, aggressive traders “must go long” Regeneron’s stock.

On June 7, REGN stock opened for trade at a price-earnings ratio of 25.5, not far from that of the general market. Regeneron’s market capitalization of $34 billion is less than six times last year’s sales of $5.9 billion, up from $4.9 billion a year earlier.

That’s not cheap, but it is fair. In the current market, however, fair looks cheap.

On a day when Berkshire Hathaway Inc. (NYSE:BRK.A) CEO Warren Buffett and JPMorgan Chase & Co. (NYSE:JPM) CEO Jamie Dimon are all over TV railing against short-term thinking based on quarterly earnings estimates, the message to buy companies like Regeneron could not be clearer.

Reason to Buy REGN Stock

What I like about Regeneron is that it pays almost no attention to Wall Street, focusing instead on using its own tools and expanding their use. A recent deal with Zoetis Inc. (NYSE:ZTS) on veterinary treatments is typical.

Zoetis has a five-year license to use Regeneron’s VelocImmune antibody discovery system, and Regeneron will let Zoetis use some of the antibodies in its pipelines to treat things like osteoarthritis in dogs and cats. Those results will help focus Regeneron’s work using the same types of antibodies in humans.

Regeneron chairman Roy Vagelos, CEO Len Schleifer, and president George Yancopoulos are all scientists. They’re not marketers or number crunchers. They focus on fundamental technology, confident that new drugs will come out the back end. It’s a futuristic, “blue sky” approach based on scientific blocking-and-tackling.

Yancopoulos says the company will stay relevant by putting things like its Regeneron Genetics Center in the hands of young scientists hungry for discovery. It’s an academic-oriented method for corporate renewal. As the father of a young scientist myself, it speaks to me. It makes sense.

Bottom Line on REGN Stock

My advice is that you buy Regeneron, when it’s cheap, and hold it … it will become dear when fashion turns toward it.

Right now, REGN stock is still relatively cheap. Analysts are expecting just $1.58 billion in revenue for the June quarter, to be reported Aug. 2, and $4 .39 per share of earnings (about $472 million). Those are modest targets, which it will probably beat, because it usually does beat estimates.

This gives you about a month or so to load up on Regeneron shares. Then put it in the back of your portfolio and forget it. Don’t even think of selling until analysts start talking about biotech overheating. Then, sell enough to get back your investment, wait for the inevitable fall and buy some more.

Dana Blankenhorn is a financial and technology journalist. He is the author of the historical mystery romance The Reluctant Detective Travels in Time, available now at the Amazon Kindle store. Write him at [email protected] or follow him on Twitter at @danablankenhorn. As of this writing, he was long REGN stock.

More From InvestorPlace

Compare Brokers

The post The Bull Case for Regeneron Pharmaceuticals Inc Couldn’t Be More Clear appeared first on InvestorPlace.

Leave a Reply

Your email address will not be published. Required fields are marked *